Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (7558)	12/19/2002 2:50:19 PM
From: Icebrg	Respond to of 52153

Ian >>If I remember correctly, it has two other Sepsis treatments in the pipeline.>> One, IC14 which started its first phase II in August. >>Doesn't the PAFASE result raise doubts about the preclinical work done on its other Sepsis Candidates?>> I would like to suggest: "Not really". Icos is not the first and most probably not the last company that has got the wrong readings on the product candidate's efficacy for the sepsis indication. I suppose a mice's sepsis isn't behaving like man's does. Then I would rather be more concerned about their phase II trial. At that point in time they should really have had an idea about the drug's potential before rushing into a major phase III. The results from the phase II was reported to be very good. Much better than for example Xigris. Erik